This all-oral combo targets a specific subgroup of NSCLC patients whose tumors progressed after EGFR-TKI therapy. The SAFFRON Phase III trial showed it significantly improved both progression-free and overall survival versus chemo. What makes this exciting? It’s biomarker-directed; meaning treatment is matched to tumor biology; and avoids traditional chemotherapy. If approved, it could become the first chemo-free option for this high-need patient group in the US. HUTCHMED’s CEO called it a major milestone, especially since the combo is already approved in China. This is science in action: targeted, precise, and patient-focused. For aspirants in biotech or medicine; watch how regulatory pathways like NDAs turn clinical data into real-world therapies.